March 7, 2024
Via: Biopharma DiveWith national polls showing Biden trailing former President Trump, Thursday’s State of the Union address is taking on outsized importance. Biden will be working to remind Americans of his accomplishments in office and persuade them that he can get even […]
March 4, 2024
Via: Biopharma DiveFor the second time in less than a month, a federal court has rejected a pharmaceutical industry lawsuit challenging the drug pricing powers Medicare was granted by the Inflation Reduction Act. The U.S. District Court for the District of Delaware […]
January 22, 2024
Via: PharmaphorumThe independent Vermont lawmaker is calling on J&J’s Joaquin Duato and Merck’s Robert Davis to explain personally why their medicines generally cost much more in the US. The two CEOs refused to testify in front of the HELP committee last […]
January 9, 2024
Via: PMLiVEPrescription drug pricing has been an ongoing issue in the US, which is reportedly spending more than double the average amount spent by other OECD member countries on prescription medicines per capita. Florida’s Canadian Prescription Drug Importation Program, which will […]
January 5, 2024
Via: Drugs.comThe U.S. Food and Drug Administration on Friday gave the nod to a Florida plan to import drugs from Canada at much lower prices than in the United States. The approval could prove to be a major turning point for […]
December 7, 2023
Via: PharmaphorumThe proposed framework for so-called ‘march-in rights’ on taxpayer-funded drugs and other inventions is the latest entry in the US federal government’s playbook to limit price increases for drugs, and will no doubt throw it once again into open contention […]
October 19, 2023
Via: Kaiser Health NewsA Senate committee finally held a hearing Wednesday on President Joe Biden’s pick to lead the National Institutes of Health. But the panel’s chair, Sen. Bernie Sanders (I-Vt.), was focused on drug prices — an issue over which the NIH […]
August 30, 2023
Via: Kaiser Health NewsThe Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major turning point in a long-fought battle to control ever-rising drug prices for […]
August 1, 2023
Via: Biopharma DiveThe acquisition is a quiet end for EQRx, which was launched three years ago by biotech venture capitalist Alexis Borisy and quickly became one of the sector’s most closely watched startups. EQRx formed with an unusual mission to develop lower-cost […]
July 19, 2023
Via: Biopharma DiveThe U.S. has long been the most lucrative market for pharmaceutical makers, in part because there are no mechanisms such as price negotiations to control the cost of medicines. As a result, Americans pay more than three times as much […]
February 8, 2023
Via: Biopharma DivePresident Biden doubled down on efforts to rein in prescription drug prices during his State of the Union address on Tuesday and warned Republicans that he will fight any attempts to roll back his initiatives. Biden called on lawmakers to […]
January 17, 2023
Via: PMLiVEThe companies will now come under the alternative statutory scheme imposed by the government through law, demonstrating what the ABPI describes as ‘the depth of feeling that the current voluntary scheme is damaging the UK life sciences industry’. Introduced in […]
January 13, 2023
Via: PharmaphorumThe lawsuit also takes aim at the three largest pharmacy benefit managers (PBMs) in the US – CVS Caremark, Express Scripts, and OptumRx – which are accused of adopting a system of rebates that incentivise manufacturers to raise list prices […]
January 9, 2023
Via: PharmaphorumThe US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of disease who have confirmed presence of amyloid pathology. Eisai and […]
December 14, 2022
Via: Kaiser Health NewsThe Biden administration is facing mounting pressure from states to let them import medicine from Canada to help lower prescription drug costs. Colorado on Dec. 5 became at least the fourth state to seek federal permission to use the strategy, […]
December 7, 2022
Via: PharmaphorumPricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. The HTA body, the CT (Commission de la Transparence – Transparency Commission), is charged with providing guidance […]
November 21, 2022
Via: PharmaphorumThe company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the […]
Industry, Pricing, Regulations, Vaccines
October 24, 2022
Via: PharmaphorumFor over two years now, the US government has been running its public vaccination campaign – the largest in American history – and has purchased all of the Covid vaccines administered in the States, including over 500 million doses from […]
October 3, 2022
Via: PharmaphorumAmylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 […]
August 15, 2022
Via: Biopharma DiveThe pharmaceutical industry is gearing up to minimize the effect of major drug legislation passed by Congress on Friday, the first time in many years lawmakers have overcome the drug lobby’s opposition to limits on their pricing power. On Friday, […]